Ozempic, Wegovy, Mounjaro or Zepbound not working? Slow responders and plateaus in the trials
Reviewed 13 sourcesPublished by PepVault
GLP-1 not working? The four labels side by side: how many lost under 5% in the trials, why diabetes slows loss, slow starters, and what a higher dose did.

- Last reviewed
- Sources
- 13
- Questions
- 7
- Compounds
- 2
The short answer
Often it is too early. Every label starts on a dose meant only to begin: Wegovy reaches 2.4 mg in week 17, Zepbound 15 mg in week 21 at the earliest. On the top doses, 84 to 91% of trial participants without diabetes lost at least 5%, fewer with diabetes, and most tirzepatide users below 5% at week 12 had passed it by week 72.
Evidence: FDA labels for all four drugs and randomised phase 3 trials in people, with responder shares from the labels; slow-responder data from a Lilly-run post-hoc analysis of SURMOUNT-1; NICE guidance for the 6-month test.

Is my GLP-1 not working, or is it too early?
Most early stalls happen on doses never meant to do the work. Wegovy starts at 0.25 mg and reaches its 2.4 mg maintenance dose only in week 171. Zepbound's label says its 2.5 mg starting dose 'is for treatment initiation and is not approved as a maintenance dosage', and each step after it lasts at least four weeks, so 15 mg arrives in week 21 at the earliest2.
PepVault's dose log keeps every shot with its date and amount, so you can see which step you are on and how many weeks you have been on it. Log it in PepVault
| Label (as of November 20, 2026) | Approved for | How the dose climbs | Highest dose | Earliest week on it |
|---|---|---|---|---|
| Ozempic3 | Type 2 diabetes, with heart and kidney risk | 0.25 mg for 4 weeks, then 0.5 mg; 1 mg and 2 mg 'if additional glycemic control is needed', each after 4+ weeks | 2 mg | 13 |
| Wegovy1 | Weight, heart risk, MASH liver disease | 0.25, 0.5, 1 and 1.7 mg, four weeks each; 7.2 mg only after 4+ weeks on 2.4 mg | 2.4 mg (7.2 mg) | 17 (for 2.4 mg) |
| Mounjaro4 | Type 2 diabetes, with heart risk | 2.5 mg, then 2.5 mg more after 4+ weeks 'if additional glycemic control is needed' | 15 mg | 21 |
| Zepbound2 | Weight, sleep apnea | 2.5 mg for 4 weeks, then 2.5 mg more after 4+ weeks | 15 mg | 21 |
On Ozempic and Mounjaro, the labels raise the dose for blood sugar, not weight, so someone whose sugar is under control can stay on a lower dose than the obesity trials used34. And a new step keeps building for weeks. Semaglutide's half-life, the time the body takes to clear half a dose, is about a week; tirzepatide's is five to six days12. A weekly drug settles at its steady state (pepvault.app/glossary/steady-state) after about four to five half-lives, roughly a month, and semaglutide's steady-state level rose in proportion to the dose all the way to 7.2 mg1.
Try it
How Semaglutide builds up
An estimate from a half-life of about 6.9 days, one dose a week for four weeks. The shape of the level, not a measurement.
Missed doses reset the clock too. After two or more missed Wegovy doses in a row, the label restarts the climb at a lower dose1.

How many people lost less than 5% in the trials?
Fewer than one in six on the top doses, counting everyone who was randomised, including people who stopped the drug. The Wegovy and Zepbound labels give the share of each group that reached three marks12. A 5% loss is 5 kg, or 11 lb, from a start of 100 kg (220 lb).
| Trial in the label, no diabetes | Group | Lost 5% or more | Lost 10% or more | Lost 15% or more |
|---|---|---|---|---|
| Wegovy Study 2 (STEP 1), 68 weeks1 | Placebo | 31.1% | 12% | 4.8% |
| Wegovy Study 2 (STEP 1), 68 weeks1 | 2.4 mg | 83.5% | 66.1% | 47.9% |
| Wegovy Study 8 (STEP UP), 72 weeks1 | Placebo | 38.3% | 20.3% | 7.5% |
| Wegovy Study 8 (STEP UP), 72 weeks1 | 2.4 mg | 86.6% | 72% | 52.3% |
| Wegovy Study 8 (STEP UP), 72 weeks1 | 7.2 mg | 88.7% | 79.8% | 63.8% |
| Zepbound Study 1 (SURMOUNT-1), 72 weeks2 | Placebo | 34.5% | 18.8% | 8.8% |
| Zepbound Study 1 (SURMOUNT-1), 72 weeks2 | 5 mg | 85.1% | 68.5% | 48.0% |
| Zepbound Study 1 (SURMOUNT-1), 72 weeks2 | 10 mg | 88.9% | 78.1% | 66.6% |
| Zepbound Study 1 (SURMOUNT-1), 72 weeks2 | 15 mg | 90.9% | 83.5% | 70.6% |
A loss under 5% happened to about 16.5% of people on Wegovy 2.4 mg in STEP 1 and 9.1% on Zepbound 15 mg, and each higher dose moved more people past every mark, most of all at 15%. Counting only what people weighed, without filling in the missing weights, STEP 1's paper puts the 5% share on semaglutide at 86.4%5. A 2026 review of response to these drugs puts non-response, a loss under 5%, at about 10% of people without diabetes in controlled trials, and higher in everyday practice10.
The label shares come from statistical models that fill in missing weights, and every group also had diet and activity counselling. About a third of the placebo groups reached 5% without the drug.
Does type 2 diabetes slow weight loss on a GLP-1?
Yes, in every pair of label trials run at the same dose. With type 2 diabetes, a third of people on Wegovy 2.4 mg stayed under 5% in STEP 2, against about one in six without diabetes in STEP 11.
| Trial in the label, type 2 diabetes | Group | Lost 5% or more | Lost 10% or more | Lost 15% or more |
|---|---|---|---|---|
| Wegovy Study 3 (STEP 2), 68 weeks1 | Placebo | 30.2% | 10.2% | 4.3% |
| Wegovy Study 3 (STEP 2), 68 weeks1 | 2.4 mg | 67.4% | 44.5% | 25.1% |
| Wegovy Study 9 (STEP UP T2D), 72 weeks1 | Placebo | 34% | 11.2% | 6.9% |
| Wegovy Study 9 (STEP UP T2D), 72 weeks1 | 2.4 mg | 74% | 49.5% | 27% |
| Wegovy Study 9 (STEP UP T2D), 72 weeks1 | 7.2 mg | 83.7% | 60.7% | 39.8% |
| Zepbound Study 2 (SURMOUNT-2), 72 weeks2 | Placebo | 32.5% | 9.5% | 2.7% |
| Zepbound Study 2 (SURMOUNT-2), 72 weeks2 | 10 mg | 79.2% | 60.5% | 39.7% |
| Zepbound Study 2 (SURMOUNT-2), 72 weeks2 | 15 mg | 82.8% | 64.8% | 48.0% |
The diabetes labels' own trials, run at diabetes doses, show smaller averages still. In Ozempic's 30-week trial of the drug on its own, people lost 3.8 kg on 0.5 mg and 4.7 kg on 1 mg, against 1.2 kg on placebo3. In Mounjaro's 40-week trial against semaglutide 1 mg, the semaglutide group lost 5.7 kg and the tirzepatide groups 7.6, 9.3 and 11.2 kg on 5, 10 and 15 mg4. A 2026 meta-analysis of 33 semaglutide trials found that a third of all participants did not reach 5%, and that up to 79.8% of those with type 2 diabetes did not reach 10%9.
Do slow starters catch up?
On tirzepatide, most did. A post-hoc analysis (pepvault.app/glossary/post-hoc-analysis), a second look at trial data after the trial ended, sorted 1,545 participants of SURMOUNT-1, the 72-week trial behind Zepbound6, who took at least 75% of their doses, by their loss at week 127. 278 of them, 18%, had lost under 5% by then. By week 24, 70% of these late responders had passed 5%; by week 72, 90% had, after about 25 weeks on average.
| SURMOUNT-1, at week 727 | Late responders (under 5% at week 12) | Early responders (5% or more at week 12) |
|---|---|---|
| Average loss, all doses | 11.0% | 22.5% |
| Average loss on 5, 10 and 15 mg | 8.3%, 11.4%, 13.6% | 18.4%, 24.1%, 24.9% |
| Lost 10% or more | 59% | 97% |
| Lost 15% or more | 30% | 84% |
Only 28 people, 1.8% of the whole group, still had under 5% at week 727. Late responders were more often men (45% against 30%) and started heavier (110.2 against 103.6 kg). The authors, most of them Lilly employees, write that this challenges the usual 12-week check for whether a drug works. A 2026 review finds that no single trait at the start reliably predicts response, and that early response on treatment is the most useful sign there is10.
Does a higher dose or a different GLP-1 help?
Wegovy's label allows 7.2 mg 'for patients who tolerate the 2.4 mg dosage for at least 4 weeks and additional weight reduction is clinically indicated'; in STEP UP, 7.2 mg averaged an 18.8% loss at 72 weeks against 15.5% on 2.4 mg, counting everyone1. Zepbound's label tells prescribers to 'consider treatment response and tolerability when selecting the maintenance dosage'2.
Head to head, tirzepatide led. In SURMOUNT-5, 751 adults without diabetes took the highest dose each could tolerate of tirzepatide (10 or 15 mg) or semaglutide (1.7 or 2.4 mg) for 72 weeks. Weight fell 20.2% against 13.7%, and more people on tirzepatide reached every mark from 10% to 25%8. The trial was open-label, meaning everyone knew which drug they took, and Lilly paid for it. Whether to raise a dose or switch drugs is the prescriber's decision.
When is a stall a plateau, and when is it time to ask?
A plateau comes to nearly everyone in the end. In a SURMOUNT-1 analysis of people who stayed on tirzepatide and lost 5% or more, the median time to a plateau was 24 to 36 weeks, depending on starting BMI, and about 88 to 90% had reached one by week 7213; the guide Retatrutide not working explains why the body pushes back. British guidance sets a clear test. NICE says to consider stopping semaglutide if less than 5% of the starting weight is lost after 6 months11, and, for tirzepatide, to decide whether to continue if less than 5% is lost after 6 months on the highest tolerated dose12.
- Write down the date of every dose step and every missed dose, and count the weeks since you reached your current dose.
- Weigh yourself at the same time of day, three or more mornings a week, and compare weekly averages, never one day against the next.
- Compare your week and dose with the tables above, using the diabetes rows if you have type 2 diabetes.
- At six months, and at six months on your highest tolerated dose, work out your loss as a share: kilograms lost, divided by starting weight, times 100.
- Take the log to your prescriber, who decides on the dose, a switch or another treatment.
PepVault's weight log charts every weigh-in over time, and the doctor's report puts your doses, start weight and weight change on one page for the appointment. Track your weight in PepVault
Commonly reported: the scale holding still for a week or two after a step-up, then moving again; loss arriving in steps rather than a smooth line; appetite creeping back in the last days before the next shot; and a fast start that slows after a few months. In our reading of public reports, 1 of 77 people on tirzepatide and 1 of 41 on semaglutide described no effect at all (pepvault.app/peptides/tirzepatide/reviews and /peptides/semaglutide/reviews).
When to get help Change or skip dose steps only with your prescriber, and contact them the same day if vomiting or diarrhoea stops you keeping fluids down, since the labels warn that the fluid loss can strain the kidneys12.
Where are the labels and trials on PepVault?
- The drugs: pepvault.app/drugs/ozempic, /drugs/wegovy, /drugs/mounjaro, /drugs/zepbound and /drugs.
- The compounds: pepvault.app/peptides/semaglutide/how-long-to-work and /peptides/tirzepatide/how-long-to-work.
- The trials: pepvault.app/research/semaglutide-step-1-2021, /research/semaglutide-step-2-2021, /research/semaglutide-step-up-2025, /research/tirzepatide-surmount-1-2022, /research/tirzepatide-surmount-2-2023, /research/tirzepatide-surmount-5-2025 and /research/tirzepatide-surmount-1-and-surmount-4-2025.
- The terms: pepvault.app/glossary/titration, /glossary/steady-state, /glossary/placebo and /glossary/post-hoc-analysis.
Sources
- WEGOVY (semaglutide) injection and tablets. Prescribing information. Novo Nordisk. DailyMed SPL version 19, published June 30, 2026. dailymed.nlm.nih.gov
- ZEPBOUND (tirzepatide) injection. Prescribing information. Eli Lilly and Company. DailyMed SPL version 40, published September 2, 2026. dailymed.nlm.nih.gov
- OZEMPIC (semaglutide) injection. Prescribing information. Novo Nordisk. DailyMed SPL version 20, published June 10, 2026. dailymed.nlm.nih.gov
- MOUNJARO (tirzepatide) injection. Prescribing information. Eli Lilly and Company. DailyMed SPL version 40, published September 2, 2026. dailymed.nlm.nih.gov
- Wilding JPH et al.; STEP 1 Study Group. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021. PubMed 33567185
- Jastreboff AM et al.; SURMOUNT-1 Investigators. Tirzepatide once weekly for the treatment of obesity. N Engl J Med. 2022. PubMed 35658024
- Ard J et al. Weight reduction over time in tirzepatide-treated participants by early weight loss response: post hoc analysis in SURMOUNT-1. Diabetes Obes Metab. 2025. PubMed 40677091
- Aronne LJ et al.; SURMOUNT-5 Trial Investigators. Tirzepatide as compared with semaglutide for the treatment of obesity. N Engl J Med. 2025. PubMed 40353578
- Ko D et al. Suboptimal therapeutic responses associated with semaglutide in type 2 diabetes and obesity: a meta-analysis of randomized controlled trials. Cell Rep Med. 2026. PubMed 41850241
- Kuryłowicz A, Czupryniak L. Responders vs. non-responders or how to predict the response to GLP-1 or GLP-1/GIP receptor agonist therapy. Diabetes Obes Metab. 2026. PubMed 42634284
- NICE. Semaglutide for managing overweight and obesity. Technology appraisal guidance TA875, recommendation 1.2. nice.org.uk
- NICE. Tirzepatide for managing overweight and obesity. Technology appraisal guidance TA1026, recommendation 1.2. nice.org.uk
- Horn DB et al. Time to weight plateau with tirzepatide treatment in the SURMOUNT-1 and SURMOUNT-4 clinical trials. Clin Obes. 2025. PubMed 39800653
Newsletter · Weekly
The weekly peptide briefing.
New guides, the week’s peptide news, one tool. Free, one email a week, unsubscribe anytime.